Novartis Home

The Novartis Compound Library provides automated storage for experiments.

At Novartis, we are reimagining medicine

Novartis statement on Zolgensma

Novartis stands behind Zolgensma® for the treatment of children less than 2 years of age with spinal muscular atrophy.

A Cell Processing Specialist at work in Novartis’ new cell and gene production facility in Stein, Switzerland.

Hardwiring the future

A Cell & Gene production unit staffed by a highly trained team at Novartis will soon begin operating in Stein, Switzerland.

Novartis Financial Results – Q2 2019

Novartis announced the company’s financial results for the second quarter and first half of 2019.

Transparency

Disclosure of transfers of value to healthcare professionals and support to patient groups in accordance with EFPIA Codes and other local laws and regulations.

Payments to Healthcare Professionals
Patient Organization Funding

Novartis Home

At Novartis, we are reimagining medicine

Novartis statement on Zolgensma

Hardwiring the future

Novartis Financial Results – Q2 2019

Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi® (etanercept-szzs) US patent case

Novartis stands behind Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of children less than 2 years of age with spinal muscular atrophy

Novartis Kisqali significantly prolongs life in women with HR+/HER2- advanced breast cancer now in two distinct Phase III trials

Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF)